GlassScriptPhysician profile
Christopher S Manganaris
NPI 1447394648
$7,761.33
in general payments reported to CMS, 2019-2025
21 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $1,018 · 2021: $487 · 2022: $733 · 2023: $995 · 2024: $1,547 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,646 · Education: $98.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,646.30 |
| Education | $98.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,320.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $781.71 | 2019-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $723.15 | 2019-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $660.56 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.09 | 2019-2025 | Ofev, Jascayd |
| Axsome Therapeutics, INC. | $540.39 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $515.18 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $380.43 | 2024-2025 | Dupixent |
| Genzyme Corporation | $308.01 | 2023-2025 | |
| Harmony Biosciences LLC | $244.37 | 2020-2025 | |
| Amgen INC. | $190.71 | 2024-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $173.72 | 2019 | |
| Insmed, INC. | $127.64 | 2021-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $81.35 | 2020 | |
| Inogen, INC. | $40.70 | 2022-2023 | Inogen At Home Stationary Concentrator |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.53 | 2021 | |
| Lilly USA, LLC | $24.23 | 2025 | Zepbound |
| Viatris Specialty LLC | $23.99 | 2025 | Yupelri |
| Advanced Respiratory, INC | $21.01 | 2021 | |
| Novo Nordisk INC | $15.16 | 2019 | |
| Merck Sharp & Dohme LLC | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Manganaris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.